- •Preface
- •Contents
- •1 Extracellular and Intracellular Signaling – a New Approach to Diseases and Treatments
- •1.1 Introduction
- •1.1.1 Linear Model of Drug Receptor Interactions
- •1.1.2 Matrix Model of Drug Receptor Interactions
- •1.2 Experimental Approaches to Disease Treatment
- •1.3 Adipokines and Disease Causation
- •1.4 Questions in Disease Treatment
- •1.5 Toxic Lifestyles and Disease Treatment
- •References
- •2.1 Introduction
- •2.2 Heterogeneity of Adipose Tissue Composition in Relation to Adipokine and Cytokine Secretion
- •2.3 Feedback between FA and the Adipocyte
- •2.6 Metabolic Programming of Autocrine Signaling in Adipose Tissue
- •2.8 Cell Heterogeneity in the Pancreatic Islet
- •2.16 Concluding Remarks
- •Acknowledgements
- •References
- •3 One Receptor for Multiple Pathways: Focus on Leptin Signaling
- •3.1 Leptin
- •3.2 Leptin Receptors
- •3.3 Leptin Receptor Signaling
- •3.3.4 AMPK
- •3.3.5 SOCS3
- •3.4 Leptin Receptor Interactions
- •3.4.1 Apolipoprotein D
- •3.4.2 Sorting Nexin Molecules
- •3.4.3 Diacylglycerol Kinase Zeta
- •3.4.4 Apolipoprotein J
- •References
- •4.1 Introduction
- •4.2 Leptin: A Brief Introduction
- •4.3 Expression of Leptin Receptors in Cardiovascular Tissues
- •4.6 Post Receptor Leptin Signaling
- •4.6.2 Mitogen Activated Protein Kinase Stimulation
- •4.7 Adiponectin
- •4.7.1 Adiponectin and Cardiovascular Disease
- •4.7.2 Adiponectin and Experimental Cardiac Hypertrophy
- •4.8 Resistin
- •4.8.1 Cardiac Actions of Resistin
- •4.8.1.1 Experimental Studies on the Cardiac Actions of Resistin
- •4.9 Apelin
- •4.9.1 Apelin and Heart Disease
- •4.10 Visfatin
- •4.11 Other Novel Adipokines
- •4.12 Summary, Conclusions and Future Directions
- •Acknowledgements
- •References
- •5 Regulation of Muscle Proteostasis via Extramuscular Signals
- •5.1 Basic Protein Synthesis
- •5.2.1 Hormones
- •5.2.1.1 Mechanisms of Action: Glucocorticoids
- •5.2.1.2 Mechanisms of Action: TH (T3)
- •5.2.1.3 Mechanisms of Action: Testosterone
- •5.2.1.4 Mechanisms of Action: Epinephrine
- •5.2.2 Local Factors (Autocrine/Paracrine)
- •5.2.2.1 Mechanisms of Action: Insulin/IGF Spliceoforms
- •5.2.2.2 Mechanisms of Action: Fibroblast Growth Factor (FGF)
- •5.2.2.3 Mechanisms of Action: Myostatin
- •5.2.2.4 Mechanisms of Action: Cytokines
- •5.2.2.5 Mechanisms of Action: Neurotrophins
- •5.2.2.7 Mechanisms of Action: Extracellular Matrix
- •5.2.2.8 Mechanisms of Action: Amino Acids (AA)
- •5.3 Regulation of Muscle Proteostasis in Humans
- •5.3.1 Nutrients as Regulators of Muscle Proteostasis in Man
- •5.3.2 Muscular Activity (i.e. Exercise) as a Regulator of Muscle Proteostasis
- •5.4 Conditions Associated with Alterations in Muscle Proteostasis in Humans
- •5.4.2 Disuse Atrophy
- •5.4.3 Sepsis
- •5.4.4 Burns
- •5.4.5 Cancer Cachexia
- •References
- •6 Contact Normalization: Mechanisms and Pathways to Biomarkers and Chemotherapeutic Targets
- •6.1 Introduction
- •6.2 Contact Normalization
- •6.3 Cadherins
- •6.4 Gap Junctions
- •6.5 Contact Normalization and Tumor Suppressors
- •6.6 Contact Normalization and Tumor Promoters
- •6.7 Conclusions
- •References
- •7.1 Introduction
- •7.2 Background on Migraine Headache
- •7.3 Migraine and Neuropathic Pain
- •7.4 Role of Astrocytes in Pain
- •7.5 Adipokines and Related Extracellular Signalling
- •7.6 The Future of Signaling Research to Migraine
- •Acknowledgements
- •References
- •8.1 Alzheimer’s Disease
- •8.1.2 Target for AD Therapy
- •8.2 AD and Metabolic Dysfunction
- •8.2.1 Impaired Glucose Metabolism
- •8.2.2 Lipid Disorders
- •8.2.3 Obesity
- •8.3 Adipokines
- •8.3.1 Leptin
- •8.3.2 Adiponectin
- •8.3.3 Resistin
- •8.3.4 Visfatin
- •8.3.5 Plasminogen Activator Inhibitor
- •8.3.6 Interleukin-6
- •8.4 Conclusions
- •References
- •9.1 Introduction
- •9.1.1 Structure and Function of Astrocytes
- •9.1.1.1 Morphology
- •9.1.1.2 Astrocyte Functions
- •9.1.2 Responses of Astrocytes to Injury
- •9.1.2.1 Reactive Astrocytosis
- •9.1.2.2 Cell Swelling
- •9.1.2.3 Alzheimer Type II Astrocytosis
- •9.2 Intracellular Signaling System in Reactive Astrocytes
- •9.2.1 Oxidative/Nitrosative Stress (ONS)
- •9.2.2 Protein Kinase C (PKC)
- •9.2.5 Signal Transducer and Activator of Transcription 3 (STAT3)
- •9.3 Signaling Systems in Astrocyte Swelling
- •9.3.1 Oxidative/Nitrosative Stress (ONS)
- •9.3.2 Cytokines
- •9.3.3 Protein Kinase C (PKC)
- •9.3.5 Protein Kinase G (PKG)
- •9.3.7 Signal Transducer and Activator of Transcription 3 (STAT3)
- •9.3.10 Ion Channels/Transporters/Exchangers
- •9.4 Conclusions and Perspectives
- •Acknowledgements
- •References
- •10.1 Adipokines, Toxic Lipids and the Aging Brain
- •10.1.1 Toxic Lifestyles, Adipokines and Toxic Lipids
- •10.1.2 Ceramide Toxicity in the Brain
- •10.3 Oxygen Radicals, Hydrogen Peroxide and Cell Death
- •10.4 Gene Transcription and DNA Damage
- •10.5 Conclusions
- •References
- •11.1 Introduction
- •11.2 Cellular Signaling
- •11.2.1 Types of Signaling
- •11.2.2 Membrane Proteins in Signaling
- •11.3 G Protein-Coupled Receptors
- •11.3.1 Structure of GPCRs
- •11.3.1.1 Structure Determination
- •11.3.1.2 Structural Diversity of Current GPCR Structures
- •11.3.1.3 Prediction of GPCR Structure and Ligand Binding
- •11.3.2 GPCR Activation: Conformation Driven Functional Selectivity
- •11.3.2.2 Ligand or Mutation Stabilized Ensemble of GPCR Conformations
- •11.3.2.4 GPCR Dimers and Interaction with Other Proteins
- •11.3.3 Functional Control of GPCRs by Ligands
- •11.3.3.1 Biased Agonism
- •11.3.3.2 Allosteric Ligands and Signal Modulation
- •11.3.4 Challenges in GPCR Targeted Drug Design
- •11.4 Summary and Looking Ahead
- •Acknowledgements
- •References
- •12.1 Introduction
- •12.5.1 Anthocyanins
- •12.5.2 Gallates
- •12.5.3 Quercetin
- •12.5.5 Piperine
- •12.5.6 Gingerol
- •12.5.7 Curcumin
- •12.5.8 Guggulsterone
- •12.6.1 Phytanic Acid
- •12.6.2 Dehydroabietic Acid
- •12.6.3 Geraniol
- •12.7 Agonists of LXR that Reciprocally Inhibit NF-jB
- •12.7.1 Stigmasterol
- •12.7.3 Ergosterol
- •12.8 Conclusion
- •References
- •13.1 Introduction
- •13.2 Selective Dopaminergic Neuronal Death
- •13.3 Signaling Pathways Involved in Selective Dopaminergic Neuronal Death
- •13.3.1 Initiators and Signaling Molecules
- •13.3.1.1 Response to Oxidative and Nitrosative Stress
- •13.3.1.2 Response to Altered Proteostasis
- •13.3.1.3 Response to Glutamate
- •13.3.1.4 Other Initiators
- •13.3.2 Signal Transducers, Intracellular Messengers and Upstream Elements
- •13.3.2.2 Small GTPases
- •13.3.3 Intracellular Signaling Cascades
- •13.3.3.1 Mitogen Activated Protein Kinases (MAPK) Pathway
- •13.3.3.2 PI3K/Akt Pathway
- •13.3.3.4 Unfolded Protein Response (UPR)
- •13.3.4 Potentially Involved Intracellular Signaling Components
- •13.3.4.3 PINK1
- •13.3.5.2 Dopamine Metabolism
- •13.3.5.3 Cell Cycle
- •13.3.5.4 Autophagy
- •13.3.5.5 Apoptosis
- •13.4 Conclusions
- •References
- •Subject Index
Involvement of Adipokines in Migraine Headache |
125 |
levels. For two of the drugs, the 5HT2aR antagonist, cyproheptadine (it also is a histamine H1 antagonist, and it is worth noting that histamine is an oftneglected factor in migraine) and the calcium channel antagonist, flunarizine, a positive therapeutic outcome resulted in increased leptin levels. Although it is not clear whether this result extends to adults, it is suggestive of adipokine involvement in migraine pathology and establishes a clearly testable hypothesis. In an indication that adipokine signaling in the metabolic context may require complex combinations of regulatory substances, addition of the beta cell pancreatic hormone amylin to leptin in both rodent models and humans leads to markedly greater weight loss than to either agent or its antagonistic analog alone.17 Migraine susceptibility also changes with age, particularly in women, leading to the thought that neuroendocrine and metabolic pathways, both of which also change in the geriatric context, bear examination in migraine.
7.6 The Future of Signaling Research to Migraine
There are still many unexplored targets for potential anti-migraine drugs. In fact, it seems likely that the number of yet-to-be-explored sites greatly exceeds those already explored. One possibility that is already under active investigation is alternate locations (such as allosteric sites) on targets already considered. A good example would be the GPCR, where there are multiple regulatory interfaces on the receptors, G proteins, downstream e ectors and additional interacting molecules72,73 (also see the introductory chapter). It is tempting to suggest that the most far-reaching future research in the realm of migraine headache will be in the areas of integrative metabolism discussed in this chapter. Even should these adipokine/metabolic ideas not turn out to be the key to unraveling the mysteries of migraine headache, the approach that has been used so profitably in diabetes/metabolic research, where multiple interacting, natural substances are operative,17,78 is likely to be a fruitful strategy in migraine research.
Acknowledgements
The author would like to express deepest appreciation to the Department of Biomedical and Pharmaceutical Sciences, the Skaggs School of Pharmacy, the College of Health Professions and Biomedical Sciences, all of The University of Montana (UM), Missoula. Without the resources and human support of these units and the university, the project could not have occurred. Local research cited in this chapter was conducted under the generous and essential sponsorship of the following NIH grants: RR10169 and GM/OD 54302-01 and 02, and P20 RR 15583 to the UM COBRE Center for Structural and Functional Neurosciences from NCRR. Various lab members over the years, both undergraduate and graduate, performed work and provided friendship critical to the overall research e ort.
126 |
Chapter 7 |
References
1.J. Olesen, P. Tfelt-Hansen and M. Ashina, Cephalalgia, 2009, 29(9), 909.
2.D. Pietrobon and J. Striessnig, Nat. Rev. Neurosci., 2003, 4, 386.
3.P. J. Goadsby, A. R. Charbit, A. P. Andreou, S. Akerman and P. R. Holland, Neurosci., 2009, 161, 327.
4.R. B. Lipton, W. F. Stewart, S. Diamond, M. L. Diamond and M. Reed, Headache, 2001, 41, 646.
5.P. Koehler and P. Tfelt-Hansen, Cephalalgia, 2008, 28(11), 1126.
6.M. Filip and M. Bader, Pharmacol. Rep., 2009, 61, 761.
7.E. C. Azmitia, Int. Rev. Neurobiol., 2007, 77, 3.
8.D. E. Nichols and C. D. Nichols, Chem. Rev., 2008, 108, 1614.
9.N. M. Barnes and T. Sharp, Neuropharm., 1999, 38, 1083.
10.D. E. Hoyer, D. E. Clarke, J. R. Fozard, P. R. Hartig, G. R. Martin, E. J. Myelecharane, P. R. Saxena and P. P. A. Humphrey, Pharmacol. Rev., 1994, 46, 157.
11.S. J. Peroutka, S. Havlik and D. Oksenberg, Headache, 1993, 33, 347.
12.E. B. Russo, Handbook of Psychotropic Herbs: A Scientific Analysis of Herbal Remedies for Psychiatric Conditions, Haworth Press, New York, 2001.
13.J. T. Weber, M.-F. O’Connor, K. Hayataka, N. Colson, R. Medora, E. B. Russo and K. K. Parker, J. Nat. Prod., 1997, 60(6), 651.
14.C. C. Crawford, M. T. Huynh, A. Kepple and W. B. Jonas, Pain Physician, 2009, 12, 461.
15.G. S. Kranz, S. Kasper and R. Lanzenberger, Neurosci., 2010, 166, 1023.
16.J. L. Lukkes, G. L. Forster, K. J. Renner and C. H. Summers, Eur. J. Pharmacol., 2008, 578, 185.
17.J. L. Chan, J. D. Roth and C. Weyer, J. Investig. Med., 2009, 57, 777.
18.C. S. Karam, J. S. Ballon, N. M. Bivens, Z. Freyberg, R. R. Girgis, J. E. Lizardi-Ortiz, J. A. Lieberman and J. A. Javitch, Trends Pharmacol. Sci., 2010, 31(8), 381.
19.R. A. Opho , G. M. Terwindt, M. N. Vergouwe, R. van Eijk, P. J. Oefner,
S.M. Ho man, J. E. Lamerdin, H. W. Mohrenweiser, D. E. Bulman,
M.Ferrari, J. Haan, D. Lindhout, G. J. van Ommen, M. H. Hofker,
M.D. Ferrari and R. R. Frants, Cell, 1996, 87(3), 543.
20.S. J. Peroutka, Headache, 2004, 44, 53.
21.M. Sparaco, M. Feleppa, R. B. Lipton, A. M. Rapoport and M. E. Bigal,
Cephalalgia, 2005, 26, 361.
22.R. Ostuzzi, G. D’Andrea, F. Francesconi and F. Musco, Neurol. Sci., 2008, 29(1), S83.
23.L. Zhou, T. Williams, J. L. Lachey, T. Kishi, M. A. Cowley and L. K. Heisler, Peptides, 2005, 26, 1728.
24.K. C. Allison, R. S. Ahima, J. P. O’Reardon, D. F. Dinges, V. Sharma,
D.E. Cummings, H. Moonseong, N. S. Martino and A. J. Stunkard,
J.Clin. Endocrinol. Metab., 2005, 90(11), 6214.
Involvement of Adipokines in Migraine Headache |
127 |
25.A. Coope, M. Milanski, E. P. Araujo, M. Tambascia, M. J. A. Saad,
B.Geloneze and L. A. Velloso, FEBS Lett., 2008, 582, 1471.
26.K. B. Alstadhaug, Cephalalgia, 2009, 29, 809.
27.S. J. Konturek, J. W. Konturek, T. Pawlik and T. J. Brzozowski, Physiol. Pharmacol., 2004, 55, 137.
28.C. Anaclet, R. Parmentier, K. Ouk, G. Guidon, C. Buda, J.-P. Sastre, H. Akaoka, O. A. Sergeeva, M. Yanagisawa, H. Ohtsu, P. Franco, H. L. Haas and J.-S. Lin, J. Neurosci., 2009, 29(46), 14423.
29.Z. B. Andrews, D. Erion, R. Beiler, Z. W. Liu, A. Abizaid, J. Zigman, J. D. Elsworth, J. M. Savitt, R. DiMarchi, M. Tschoep, R. H. Roth, X. B. Gao and T. L. Horvath, J. Neurosci., 2009, 29(45), 14057.
30.B. Antuna-Puente, B. Feve, S. Fellahi and J. P. Bastard, Diabetes Metab., 2008, 34, 2.
31.A. Chakravarty and A. Sen, Med. Hypotheses, 2010, 74, 225.
32.M. Inoue, M. H. Rashid, R. Fujita, J. J. Contos, J. Chun and H. Ueda, Nat. Med., 2004, 10, 712.
33.T. Maeda, N. Kiguchi, Y. Kobayashi, T. Ikuta, M. Ozaki and S. Kishioka,
Proc. Natl. Acad. Sci. U.S.A., 2009, 106(31), 13076.
34.B. L. Peterlin, J. Am. Osteopath. Assoc., 2009, 109, 314.
35.G. D’Andrea, R. Ostuzzi, F. Francesconi, F. Musco, A. Bolner, F. d’Onofrio and D. Colavito, Neurol. Sci., 2009, 30(1), S55.
36.G. D’Andrea, G. P. Nordera, F. Perini, G. Allais and F. Granella, Neurol. Sci., 2007, 28(2), S94.
37.M. Namaka, C. Leong, A. Grossberndt, M. Klowak, D. Turcotte,
F.Esfahani, A. Gomori and H. Intrater, Consult. Pharm., 2009, 24(12), 885.
38.K. Kroenke, J. Shen, T. E. Oxman, J. W. Williams and A. J. Dietrich, Pain, 2008, 134, 209.
39.M. de Tommaso, M. Sardaro, C. Serpino, F. Costantini, E. Vecchio,
M.P. Prudenzano, P. Lamberti and P. Livrea, Cephalalgia, 2009, 29(4), 453.
40.T. A. Fiacco, C. Agulhon and K. D. McCarthy, Ann. Rev. Pharmacol. Tox., 2009, 49, 151.
41.G. Carmignoto and M. Gomez-Gonzalo, Brain Res. Rev., 2010, 63(1–2), 138.
42.E. Hansson, A. Westerlund, U. Bjorklund and T. Olsson, Neurosci., 2008, 155, 1237.
43.W. Pan, H. Hsuchou, Y. He, A. Sakharkar, C. Cain, C. Yu and A. J. Kastin, Endocrinol., 2008, 149(6), 2798.
44.W. L. Yeh, D. Y. Lu, M. J. Lee and W. M. Fu, Glia, 2009, 57, 454.
45.B. A. Barres, Neuron, 2008, 60, 430.
46.J. De Keyser, J. P. Mostert and K. W. Koch, J. Neurol. Sci., 2008, 267(1–2), 3.
47.J. L. Eriksen and M. J. Druse, Brain Res. Dev. Brain Res., 2001, 131, 9.
48.E. K. Kong, L. Peng, Y. Chen and A. C. Yu, Neurochem. Res., 2002, 27, 113.
128 |
Chapter 7 |
49.D. C. Deecher, B. D. Wilcox, V. Dave, P. A. Rossman and H. K. Kimelberg, J. Neurosci. Res., 1993, 35, 246.
50.M. Shimizu, A. Nishida, H. Zensho and S. Yamawaki, J. Pharmacol. Exp. Ther., 1996, 279, 1551.
51.B. Hall, L. Madden and K. K. Parker, Scientific Research Society Abstracts, 2006, PR–04.
52.R. C. Koehler, R. J. Roman and D. R. Harder, Trends Neurosci., 2009, 32, 160.
53.K. V. Rama Rao, M. Chen, J. M. Simard and M. D. Norenberg,
J.Neurosci. Res., 2003, 74, 891.
54.M. M. Halassa, C. Florian, T. Fellin, J. R. Munoz, S. Y. Lee, T. Abel,
P.G. Haydon and M. G. Frank, Neuron, 2009, 61(2), 213.
55.J. T. Willie, R. M. Chemelli, C. M. Sinton and M. Yanagisawa, Ann. Rev. Neurosci., 2001, 24, 429.
56.A. Okada-Ogawa, I. Suzuki, B. J. Sessle, M. W. Salter, J. O. Dostrovsky,
Y.Tsuboi, M. Kondo, J. Kitagawa, A. Kobayashi, N. Noma, Y. Imamura and K. Iwata, J. Neurosci., 2009, 29(36), 11161.
57.A. J. Ramos, M. D. Rubio, C. Defagot, L. Hirschberg, M. J. Villar and
A.Brusco, Brain Res., 2004, 1030, 201.
58.E. B. Russo, A. Burnett, B. Hall and K. K. Parker, Neurochem. Res., 2005, 30, 1037.
59.J. C. Poblete and E. C. Azmitia, Brain Res., 1995, 680, 9.
60.B. Li, S. Zhang, M. Li, L. Hertz and L. Peng, Psychopharmacol. (Berl.), 2009, 207(1), 1.
61.C. Jonnakuty and C. Gragnoli, J. Cell Physiol., 2008, 217, 301.
62.A. A. Teleman, Biochem. J., 2009, 425, 13.
63.G. L. Firestone and S. N. Sundar, Mol. Endocrinol., 2009, 23, 1940.
64.S. Damodaram, S. Thalakoti, S. E. Freeman, F. G. Garrett and P. L. Durham, Headache, 2009, 49, 5.
65.B. McEwen and E. N. Lasley, The End of Stress as We Know It, Joseph Henry Press, Washington, D. C., 2002.
66.J. Zhang, C. J. Hupfeld, S. S. Taylor, J. M. Olefsky and R. Y. Tsien, Nature, 2005, 437, 569.
67.J. C. Chuang, V. Krishnan, H. G. Yu, B. Mason, H. Cui, M. B. Wilkinson,
J.M. Zigman, J. M. Elmquist, E. J. Nestler and M. Lutter, Biol. Psychiatry, 2010, 67, 1075.
68.K. Omori and J. Kotera, Circ. Res., 2007, 100, 309.
69.R. Noseda, V. Kainz, M. Jakubowski, J. J. Gooley, C. B. Saper, K. Digree and R. Burstein, Nat. Neurosci., 2010, 13(2), 239.
70.M. Haw, Am. Sci., 2007, 95, 472.
71.T. Hirfanoglu, A. Serdaroglu, O. Gulbahar and A. Cansu, Pediatr. Neurol., 2009, 41, 281.
72.A. Ivetac and J. A. McCammon, Chem. Biol. Drug Des., 2010, 76, 201.
73.H. V. Thiagaraj, T. C. Ortiz, M. C. Devereaux, B. Seaver, B. Hall and
K.K. Parker, Neurochem. Int., 2007, 50, 109.
Involvement of Adipokines in Migraine Headache |
129 |
74.E. Hansson, A. Westerlund, U. Bjorklund and L. Ronnback, Neurorep., 2009, 20, 957.
75.A. Rachalski, C. Alexandre, J.-F. Bernard, F. Saurini, K.-P. Lesch,
M.Hamon, J. Adrien and V. Fabre, Neurosci., 2009, 29(49), 15575.
76.J. M. Wade, P. Juneja, A. W. MacKay, J. Graham, P. J. Havel, L. H. Tecott and E. H. Goulding, Endocrinol., 2008, 149(3), 955.
77.L. B. Resstel, R. F. Tavares, S. F. Lisboa, S. R. Joca, F. M. Correa and
F.S. Guimaraes, Br. J. Pharmacol., 2009, 156(1), 181.
78.C. Weyer, The Scientist, 2009, December, 35.